Fully developed. The usefulness of the materials has been shown in Dr. Moss' laboratory.
Offered for licensing is a recombinant attenuated vaccinia virus, MVA, that expresses the haemagglutinin (HA) and nucleoprotein (NP) of influenza virus A/PR/8/34 (H1N1). The virus has been shown to stimulate protective immunity to influenza virus in mice.
The materials can be used for research purposes and in particular in the area of influenza virus vaccines.
The related publications listed below demonstrate the usefulness of this biological material in influenza virus vaccine research.
CB Process - Initiated CB Process. Forwarded email to LPM. Requesting details concerning the new technology.